We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Trump announced that he would meet with pharma executives this week to discuss drug pricing and his controversial “favored nations” executive order — but PhRMA claimed it hasn’t heard of any such meeting. Read More
Centers for Disease Control and Prevention Director Robert Redfield has sent a letter to the governors of all 50 states urging them to be prepared for COVID-19 vaccine distribution by Nov. 1 — just two days ahead of the presidential election. Read More
The National Institutes of Health (NIH) on Wednesday said that there’s currently not enough data to say if convalescent plasma should be recommended or rejected as a COVID-19 treatment, doubling down on its previous advice to the FDA to delay Emergency Use Authorization (EUA) until more evidence is available. Read More
The FDA has denied a citizen’s petition from the Southern Network on Adverse Reactions (SONAR) to change the labeling on Johnson & Johnson’s antibiotic Levaquin (levofloxacin). Read More
The FDA released a straight-to-final guidance yesterday on steps drugmakers should take to prevent high levels of nitrosamine impurities in their products. Read More
When the FDA is reviewing products that include both drugs and devices in combination, a stumbling block that sometimes causes delays is poor communication between the agency's Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH), according to an independent assessment by Lexington, Mass.-based Eastern Research Group (ERG). Read More
The chair of the House Committee on Oversight and Reform has told her colleagues that she is issuing a subpoena to AbbVie as part of the committee’s ongoing investigation into how companies set drug prices. Read More
In a widely reported interview over the weekend, FDA Commissioner Stephen Hahn said the agency is prepared to issue an Emergency Use Authorization for a COVID-19 vaccine before phase 3 trials are complete if the benefits outweighed the risks. Read More
The FDA has been accused of potentially fouling up its Aug. 23 Emergency Use Authorization (EUA) of convalescent plasma (CCP) for the treatment of COVID-19 by adding a requirement that each unit of plasma include information on the concentration of antibody titres. Read More
The European Commission announced Monday that it is participating in the World Health Organization’s international COVAX program for COVID-19 vaccines and is contributing $478 million. Read More
Two COVID-19 vaccine candidates being developed by Chinese pharma companies have already received emergency authorization in China, the country’s National Medical Products Administration (NMPA) revealed. Read More